Medicinal chemistry
We design and evaluate novel small molecules for a defined therapeutic objective, taking the requirements of drug development into account from the outset.
We are developing novel small molecules to address the effects of cancer and its treatment on the nervous system.
Neural plasticity is the nervous system’s ability to adapt. We are studying its potential role in cancer supportive care.
We investigate compounds designed to engage pathways involved in neural plasticity and neuroinflammation. For our lead program, we aim to develop an oral medicine suitable for routine oncology care.
Preclinical studies are needed to establish whether these compounds produce the intended biological effects. Clinical trials would then assess whether they benefit patients.
We design and evaluate novel small molecules for a defined therapeutic objective, taking the requirements of drug development into account from the outset.
We study receptor activity, brain exposure, selectivity and safety to assess each program and determine which studies are needed next.
We plan studies of neural plasticity and functional outcomes in models relevant to cancer and its treatment.
We consider which outcomes matter to patients and how a treatment could be used in oncology care when planning our development programs.
TL-01 is a preclinical neuroplastogen research program based on serotonin receptor pharmacology.
We are initially developing TL-01 for cancer-related cognitive impairment, often called “chemo brain.” Our goal is an oral medicine that could fit routine oncology care. Reduced perceptual effects are also a research objective.
Receptor and brain exposure studies help us plan the next experiments. Direct studies of neural plasticity, further safety evaluation and research in disease models are still needed. TL-01 has not been tested in humans, so its clinical benefit, subjective effects and monitoring requirements remain unknown.
View the pipelineCancer treatment can affect thinking, memory and concentration. Read the National Cancer Institute’s overview